4.5 Article

In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions

期刊

JOURNAL OF NEUROCHEMISTRY
卷 157, 期 4, 页码 1253-1269

出版社

WILEY
DOI: 10.1111/jnc.15300

关键词

5 '-AMP-activated protein kinase; biomarkers; CDKL5 deficiency disorder (CDD); Cdkl5 mouse model; mitochondria; MRI/MRS studies

资金

  1. Fondazione Roche
  2. Fondazione CRT [2018.0889]
  3. Fondazione Telethon [GGP19045A]

向作者/读者索取更多资源

CDKL5 deficiency disorder is a severe neurodevelopmental condition caused by mutations in the X-linked CDKL5 gene, characterized by infantile epileptic encephalopathy, intellectual disability, and autistic features. Magnetic Resonance methods revealed a metabolic dysregulation suggestive of mitochondrial dysfunction in the brain of Cdkl5 deficient mice, highlighting potential therapeutic strategies targeting mitochondria.
Mutations in the X-linked CDKL5 gene cause CDKL5 deficiency disorder (CDD), a severe neurodevelopmental condition mainly characterized by infantile epileptic encephalopathy, intellectual disability, and autistic features. The molecular mechanisms underlying the clinical symptoms remain largely unknown and the identification of reliable biomarkers in animal models will certainly contribute to increase our comprehension of CDD as well as to assess the efficacy of therapeutic strategies. Here, we used different Magnetic Resonance (MR) methods to disclose structural, functional, or metabolic signatures of Cdkl5 deficiency in the brain of adult mice. We found that loss of Cdkl5 does not cause cerebral atrophy but affects distinct brain areas, particularly the hippocampus. By in vivo proton-MR spectroscopy (MRS), we revealed in the Cdkl5 null brain a metabolic dysregulation indicative of mitochondrial dysfunctions. Accordingly, we unveiled a significant reduction in ATP levels and a decrease in the expression of complex IV of mitochondrial electron transport chain. Conversely, the number of mitochondria appeared preserved. Importantly, we reported a significant defect in the activation of one of the major regulators of cellular energy balance, the adenosine monophosphate-activated protein kinase (AMPK), that might contribute to the observed metabolic impairment and become an interesting therapeutic target for future preclinical trials. In conclusion, MRS revealed in the Cdkl5 null brain the presence of a metabolic dysregulation suggestive of a mitochondrial dysfunction that permitted to foster our comprehension of Cdkl5 deficiency and brought our interest towards targeting mitochondria as therapeutic strategy for CDD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据